205 related articles for article (PubMed ID: 37949484)
1. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.
Li X; Zhu Y; Yi J; Deng Y; Lei B; Ren H
J Leukoc Biol; 2024 Apr; 115(5):866-881. PubMed ID: 37949484
[TBL] [Abstract][Full Text] [Related]
2. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
Wank R; Song X; Gu S; Laumbacher B
Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
[TBL] [Abstract][Full Text] [Related]
3. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
Mallmann P; Krebs D
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
[TBL] [Abstract][Full Text] [Related]
4. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
5. T-cell-associated cellular immunotherapy for lung cancer.
Li K; Zhang Q; Zhang Y; Yang J; Zheng J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1249-58. PubMed ID: 25381064
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
7. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
8. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.
Venetis K; Invernizzi M; Sajjadi E; Curigliano G; Fusco N
Cancer Treat Rev; 2020 Nov; 90():102089. PubMed ID: 32889360
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract][Full Text] [Related]
13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
15. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract][Full Text] [Related]
16. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
17. Current State of Cell Therapies for Breast Cancer.
Gautam N; Elleson KM; Ramamoorthi G; Czerniecki BJ
Cancer J; 2022 Jul-Aug 01; 28(4):301-309. PubMed ID: 35880940
[TBL] [Abstract][Full Text] [Related]
18. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
19. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
